Fig 1: Overall survival (OS) curves depicted for the ovarian cancer patients based on the gene expression levels of ICOS (a), TIGIT (b), TNFRSF8 (c), CD8A (d), ICOS/CD8A (e), TIGIT/CD8A (f), and TNFRSF8/CD8A (g). Samples were stratified according to the median expression value for each gene.
Fig 2: Immunohistochemistry for ICOS, TIGIT, TNFRSF8, and CD8A. Ovarian cancer samples (n = 208). Weak immunostaining scores for ICOS (a), TIGIT (c), TNFRSF8 (e), and CD8A (g) and strong immunostaining scores for ICOS (b), TIGIT (d), TNFRSF8 (f), and CD8A (h). The relative expression of the ICOS, TIGIT, TNFRSF8, and CD8A genes is depicted (i, j, k) (200×).
Fig 3: The Kaplan-Meier survival curve of different groups. (a, d) ICOS and CD8A; (b, e) TIGIT and CD8A; (c, f) TNFRSF8 and CD8A.
Supplier Page from Abcam for Anti-CD30 antibody [EPR4102]